Involving Antibody Fragments Patents (Class 436/512)
-
Patent number: 8084272Abstract: The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 ?g/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.Type: GrantFiled: March 25, 2009Date of Patent: December 27, 2011Assignee: Abbott Point of Care Inc.Inventors: John Lewis Emerson Campbell, John Emegbero Omakor
-
Publication number: 20110287559Abstract: A method of characterizing glycans attached to glycoproteins is disclosed herein. The method comprises a first step of immobilizing the glycoproteins on colloidal particles forming glycoprotein/colloidal particles. The glycans on the glycoproteins may then be characterized, for example the composition and/or structure of glycans may be characterized or the glycans attached to proteins may be identified. Characterization may be accomplished by either binding the glycoprotein/colloidal particles with one or more binding agents and assessing the aggregation of the glycoprotein/colloidal particles or by cleaving glycans from the glycoprotein/colloidal particles with a cleaving agent and analyzing the glycans.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Applicant: National Institute of Standards and TechnologyInventors: Rebecca A. Zangmeister, Germarie Sanchez-Pomales, Todd A. Morris, Michael J. Tarlov
-
Patent number: 8053226Abstract: The invention relates to a device for simultaneously, qualitatively or quantitatively identifying a number of analytes in a liquid sample. The device comprises a membrane with: a charging zone for applying the liquid sample; at least two indicator zones, which can interact with the analytes, and at least one absorption area, which absorbs the liquid after passing the indicator zones, whereby the indicator zones are located between the charging zone and an absorption area. The invention is characterized in that the flowing directions from the charging zone through the respective indicator zones to an absorption area (flow paths) are essentially parallel, and at least two different flow paths exist. The invention also relates to a method for identifying a number of analytes or the derivatives thereof in a liquid sample.Type: GrantFiled: July 8, 2004Date of Patent: November 8, 2011Assignee: Medion Diagnostics AGInventors: Peter Schwind, Klemens Löster
-
Patent number: 8048414Abstract: F(ab) fragments are isolated from an antibody containing source by contacting the antibody containing source with a papain-polyacrylamide matrix to produce F(ab) and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab) fragments. F(ab)2 fragments are obtained by contacting the antibody containing source with a pepsin-polyacrylamide matrix to produce F(ab)2 and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab)2 fragments. IgG antibodies are obtained by passing an antibody containing source through an antigen-polyacrylamide gel. These processes can be used to purify a wide variety of antibodies which can be used as therapeutic agents and as diagnostic agents. Antivenins produced by these processes have substantially reduced foreign protein levels and hence are less likely to produce immunogenic reactions.Type: GrantFiled: March 15, 1995Date of Patent: November 1, 2011Assignee: BTG International Inc.Inventors: John B. Sullivan, Findlay E. Russell
-
Patent number: 8039273Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.Type: GrantFiled: July 18, 2006Date of Patent: October 18, 2011Assignee: Seattle Genetics, Inc.Inventor: Scott Jeffrey
-
Patent number: 8012762Abstract: Test device for detection and visual indication of a specific analyte in a liquid sample such as a body fluid. The device includes a biodegradable housing, a test strip and a lid. The device is configured for placement in concentrate or dilute test liquid that is for example contained in a vessel. One end of the test strip wicks the liquid being tested into the housing and across a control site and test site which provide visual indication that the device is working correctly and whether the analyte being tested is present in the test liquid. An antibody specific to the antigen being tested may be provided on the test strip. The test device for example detects specific antigens in dilute urine, such that the device may be placed in a toilet bowl after urination.Type: GrantFiled: April 16, 2008Date of Patent: September 6, 2011Inventor: Steve Lee
-
Patent number: 8012770Abstract: Devices and methods for the detection of antigens are disclosed. Devices and methods for detecting food-borne pathogens are disclosed.Type: GrantFiled: July 31, 2009Date of Patent: September 6, 2011Assignee: Invisible Sentinel, Inc.Inventors: Nicholas A. Siciliano, Martin Joseph Bouliane
-
Patent number: 7993866Abstract: The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.Type: GrantFiled: January 12, 2009Date of Patent: August 9, 2011Assignees: Cedars-Sinai Medical Center, The Regents of the University of CaliforniaInventors: Stephan R. Targan, Jonathan Braun, Christopher L. Sutton
-
Patent number: 7994291Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.Type: GrantFiled: May 25, 2010Date of Patent: August 9, 2011Assignee: Amgen Inc.Inventors: Hui-Quan Han, Keith Kwak
-
Patent number: 7993867Abstract: The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.Type: GrantFiled: January 12, 2009Date of Patent: August 9, 2011Assignees: Cedars-Sinai Medical Center, The Regents of the University of CaliforniaInventors: Stephan R. Targan, Jonathan Braun, Christopher L. Sutton
-
Patent number: 7993865Abstract: The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.Type: GrantFiled: November 17, 2006Date of Patent: August 9, 2011Assignees: Cedars-Sinai Medical Center, The Regents of the University of CaliforniaInventors: Stephan R. Targan, Jonathan Braun, Christopher L. Sutton
-
Patent number: 7968283Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.Type: GrantFiled: June 28, 2010Date of Patent: June 28, 2011Assignee: Agensys, Inc.Inventors: Daniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell
-
Patent number: 7939282Abstract: Compositions and methods for detecting sepsis by contacting a subject-derived sample with a ligand that binds to GRK and determining the concentration of GRK in the sample. An increase in the concentration of GRK compared to that of a normal, healthy control sample indicates that the subject from which the sample is obtained is suffering from or at risk of developing sepsis.Type: GrantFiled: October 20, 2005Date of Patent: May 10, 2011Assignee: Rhode Island HospitalInventors: Loren D. Fast, Yow-Pin Lim
-
Patent number: 7935520Abstract: Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters.Type: GrantFiled: June 25, 2009Date of Patent: May 3, 2011Assignee: SRU Biosystems, Inc.Inventors: Brian T. Cunningham, Jane Pepper, Bo Lin, Peter Li, Homer Pien, Jean Qiu
-
Patent number: 7932048Abstract: The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the ?-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the ?-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the ?-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage.Type: GrantFiled: March 9, 2006Date of Patent: April 26, 2011Assignee: Consejo Superior de Investigaciones CientificasInventor: Enrique Mendez
-
Patent number: 7919255Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.Type: GrantFiled: June 17, 2004Date of Patent: April 5, 2011Assignee: Otago Innovation LimitedInventors: Timothy Charles Ramsey Prickett, Eric Arnold Espiner, Arthur Mark Richards, Timothy Grant Yandle, Michael Gary Nicholls
-
Patent number: 7910381Abstract: A chromatographic specific binding assay strip device, comprising: a non-permeable platform strip; a permeable membrane testing strip positioned on top of said non-permeable platform strip, with the testing strip comprising at least one capture reagent site containing a capture reagent for at least one specific analyte, a sample receiving pad positioned on top of and at a proximal end of the non-permeable platform strip, with the sample receiving pad having contact with a proximal end of said permeable membrane testing strip, a reservoir pad positioned on top of and at a distal end of said non-permeable membrane testing strip, with the reservoir pad having contact with a proximal end of said permeable membrane test strip; a supporting strip attached to and extending from the proximal end of said non-permeable platform strip; and a conjugate pad positioned on said supporting strip, said conjugate pad comprising a semi-permeable membrane containing a colorant conjugate.Type: GrantFiled: March 5, 2008Date of Patent: March 22, 2011Assignee: BioAssay WorksInventors: Glen Ford, Leslie Kirkegaard
-
Patent number: 7888134Abstract: An apparatus and methods for binding an analyte of interest in a sample are provided. The apparatus comprises a substrate with an exposed surface with an compound, that is electrostatically charged or capable of forming hydrogen bonds, provided bound to the solid substrate. A recombinant single chain antibody (scFv) molecule specific for the analyte of interest, having one or more amino acids with charged or hydrogen-bond forming sidechains in a linker polypeptide portion, is bound to the layer on the solid substrate. When the analyte of interest is present in the sample the scFv binds the analyte to the solid substrate. The apparatus can be used with an immunoglobulin layer to detect Fc receptors, so as to detect microorganisms such as Staphylococcus aureus having protein A or protein G.Type: GrantFiled: August 6, 2007Date of Patent: February 15, 2011Assignees: Oakland University, Vanderbilt UniversityInventors: Xiangqun Zeng, Raymond L. Mernaugh
-
Patent number: 7888050Abstract: The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.Type: GrantFiled: July 24, 2008Date of Patent: February 15, 2011Assignee: Life Technologies CorporationInventors: Kevin Reagan, Erik Schaefer, Jimin Wang
-
Patent number: 7879612Abstract: Provided are methods comprising the use of non-sugar organic compatible solutes for protection and preservation of the activity of biologically active molecules and conjugate labels. The methods are particularly adaptable for use in conjunction with immunoassays, such as for example, immunochromatographic test assays and may be incorporated into any test methodology wherein a dry test strip is used as a carrier for depositing, mobilizeable and/or immobilized biologically active molecules and/or conjugate labels.Type: GrantFiled: December 27, 2007Date of Patent: February 1, 2011Inventors: William J. Palin, Alan H. Davis, Roger N. Piasio, Erik R. Piasio, Bruce C. Reinemann
-
Label-free methods for performing assays using a colorimetric resonant reflectance optical biosensor
Patent number: 7875434Abstract: The instant invention provides compositions and methods for determining cell interactions that are faster than conventional methods and that require the use of fewer reagents than conventional methods.Type: GrantFiled: July 25, 2007Date of Patent: January 25, 2011Assignee: SRU Biosystems, Inc.Inventors: Bo Lin, Brian T. Cunningham, Peter Li -
Patent number: 7858760Abstract: A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.Type: GrantFiled: September 7, 2004Date of Patent: December 28, 2010Assignee: Agensys, Inc.Inventors: Daniel E. H. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas Saffran
-
Patent number: 7846744Abstract: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc?RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.Type: GrantFiled: April 22, 2009Date of Patent: December 7, 2010Inventors: Jeffrey V. Ravetch, Robert M Anthony
-
Patent number: 7833731Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.Type: GrantFiled: March 31, 2005Date of Patent: November 16, 2010Assignee: Canon Kabushiki KaishaInventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
-
Patent number: 7829347Abstract: A diagnostic test kit that provides an integrated system for accurately detecting a test analyte over a broad range of possible concentrations is provided. One feature of the integrated system is that it is capable of indicating whether an analyte is within the “hook effect” region. Based on this indication, a technique may be selected for correlating a measured signal intensity to an analyte concentration or range of concentrations. For example, when it is determined that the test sample falls outside the “hook effect” region, the analyte concentration may be determined using one portion of a dose response curve. On the other hand, when it is determined that the test sample falls within the “hook effect” concentration, the analyte concentration may be determined using another portion of the dose response curve. Alternatively, the sample may simply be diluted for re-performing the assay.Type: GrantFiled: August 31, 2005Date of Patent: November 9, 2010Assignee: Kimberly-Clark Worldwide, Inc.Inventor: Xuedong Song
-
Patent number: 7803554Abstract: This invention relates to a simple and quick method for the detection, identification and/or quantitation of binding factors using fluorescence techniques. A fluorescent probe is incubated with a factor or group of factors, and the presence of a factor capable of binding the probe can be detected by fluorescence polarization. When coupled with a separation step, this invention allows on-line monitoring of binding complex formation.Type: GrantFiled: January 26, 2004Date of Patent: September 28, 2010Inventor: Xiao-Chun (Chris) Le
-
Patent number: 7794970Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.Type: GrantFiled: September 18, 2006Date of Patent: September 14, 2010Assignee: Amgen Inc.Inventors: John O. Hui, Mitsuru Haniu, Hsieng Sen Lu
-
Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
Patent number: 7790861Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: GrantFiled: May 7, 2002Date of Patent: September 7, 2010Assignee: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu, Min Wang -
Patent number: 7790863Abstract: The present invention relates to angiogenesis inhibiting molecules that are the monoclonal antibody H33 or fragments or derivatives thereof, to their use in the treatment of cancer, in particular the treatment of solid tumors and to therapeutic and diagnostic compositions comprising them. The invention relates in particular to humanized derivatives of H33 of human monoclonal antibodies having the specificity of H33.Type: GrantFiled: November 19, 2004Date of Patent: September 7, 2010Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Publication number: 20100221846Abstract: In an example embodiment, there is a sensor for detecting particles. The sensor comprises an electrode, a sensor active region covering the electrode and the sensor active region is sensitive-for the particles. A first switch element is operable to bring the electrode to a first electric potential when the first switch element is closed, and a second switch element is operable to bring the electrode to a second electric potential when the second switch element is closed. A detector is adapted to detect the particles based on a change of the electric properties of the sensor in an operation mode in which the electrode is brought to the first electric potential and an operation mode in which the electrode is brought to the second electric potential.Type: ApplicationFiled: October 7, 2008Publication date: September 2, 2010Applicant: NXP B.V.Inventor: Franciscus Widdershoven
-
Patent number: 7749713Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or down-regulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: November 19, 2003Date of Patent: July 6, 2010Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7750123Abstract: The invention provides scFv antibodies and monoclonal antibodies that neutralize SARS-CoV. Also provided are methods of treating and/or preventing a coronavirus-related disease or disorder such as SARS. The invention also provides methods of vaccinating a patient against SARS-CoV. Also provided are methods of diagnosing coronavirus-related diseases or disorders and methods of detecting the presence of a coronavirus in a sample. The invention additionally provides methods of screening for compounds that modulate the binding of SARS-CoV and the SARS-CoV receptor ACE2 as well as for compounds useful to treat SARS-CoV-related diseases or disorders.Type: GrantFiled: November 24, 2004Date of Patent: July 6, 2010Assignee: Dana Farber Cancer Institute, Inc.Inventors: Wayne Marasco, Jianhua Sui
-
Patent number: 7745228Abstract: This invention relates to a device for the simultaneous qualitative or quantitative determination of several analytes in a liquid sample. The device comprises a membrane with a charging zone, for the application of the liquid sample, at least two indicator zones which can interact with the analyte(s) and at least one absorption region, which accepts the fluid after passing through the indicator zones, whereby the indicator zones lie between the charging zone and an absorption region, characterized in that the flow directions (flow tracks) are essentially parallel from the application zone through each indicator zone to an absorption region and at least two different flow tracks are present.Type: GrantFiled: July 8, 2004Date of Patent: June 29, 2010Assignee: Medion Diagnostics AGInventors: Peter Schwind, Klemens Löster
-
Patent number: 7744887Abstract: Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which encode relevant portions of these antibodies, as well as the purified forms of the expressed antibodies or relevant antibody fragments, such as VH and VL chains. The antibody compositions disclosed within this specification may provide for a therapeutic treatment against HIV infection by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV infection. These antibodies will also be useful in assays to identify HIV antiviral compounds as well as allowing for the identification of candidate HIV vaccines, such as HIV peptide vaccines.Type: GrantFiled: May 31, 2005Date of Patent: June 29, 2010Assignees: Merck & Co., Inc., Whitehead Insitute of Biomedical Research, MedImmune Limited, Istitute di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: John W. Shiver, Michael D. Miller, Romas Geleziunas, Daria J. Hazuda, Peter S. Kim, Debra M. Eckert, Michael J. Root, Simon N. Lennard, Elisabetta Bianchi
-
Patent number: 7745586Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.Type: GrantFiled: August 6, 2008Date of Patent: June 29, 2010Assignee: Amgen Inc.Inventors: Hui-Quan Han, Keith Kwak
-
Patent number: 7741443Abstract: The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.Type: GrantFiled: December 22, 2005Date of Patent: June 22, 2010Assignee: Crucell Holland B.V.Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianus Q. Bakker, Alexander Berthold Hendrik Bakker
-
Patent number: 7741128Abstract: The present invention relates to methods and compositions to detect analytes in a sample using antibody molecules that are transformed into nanoscale “self-signaling” biosensors. It relates in particular to those methods and compositions that provide for single-step detection of target analytes without the need for labor-intensive steps necessary in conventional assays.Type: GrantFiled: May 23, 2006Date of Patent: June 22, 2010Assignee: University of HawaiiInventor: Wei Wen Su
-
Patent number: 7741055Abstract: The present invention relates to human PGF polypeptides and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques, and antibodies and antagonist/inhibitors against such polypeptides. Also provided are methods of using such polypeptides therapeutically for treating prostate cancer, to promote tissue regeneration and to facilitate wound healing. Also provided is a diagnostic assay to detect prostate cancer and benign prostatic hyperplasia.Type: GrantFiled: February 23, 2007Date of Patent: June 22, 2010Assignee: Human Genome Sciences, Inc.Inventors: Peter L. Hudson, Craig A. Rosen, Wei-Wu He
-
Patent number: 7728115Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.Type: GrantFiled: August 2, 2005Date of Patent: June 1, 2010Assignee: STC. UNMInventors: Gowthami M. Arepally, Walter Kisiel, Keiko Kamei, Shintaro Kamei
-
Patent number: 7691583Abstract: A system and method for detecting mass based on a frequency differential of a resonating micromachined structure, such as a cantilever beam. A high aspect ratio cantilever beam is coated with an immobilized binding partner that couples to a predetermined cell or molecule. A first resonant frequency is determined for the cantilever having the immobilized binding partner. Upon exposure of the cantilever to a solution that binds with the binding partner, the mass of the cantilever beam increases. A second resonant frequency is determined and the differential resonant frequency provides the basis for detecting the target cell or molecule. The cantilever may be driven externally or by ambient noise. The frequency response of the beam can be determined optically using reflected light and two photodetectors or by interference using a single photodetector.Type: GrantFiled: January 31, 2006Date of Patent: April 6, 2010Assignee: Cornell Research Foundation, Inc.Inventors: Harold G. Craighead, Bojan Ilic, David Alan Czaplewski, Robert H. Hall
-
Patent number: 7662928Abstract: Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.Type: GrantFiled: December 6, 2006Date of Patent: February 16, 2010Assignee: The Research Foundation of State University of New YorkInventors: Joseph P. Balthasar, Ryan J. Hansen, Feng Jin
-
Patent number: 7659083Abstract: A construct is provided that is capable of binding a plurality of molecules, the construct comprising a first moiety with a first molecule binding region and a first molecule non-binding region; and a second moiety with a second molecule-binding region and a second molecule-non-binding region, whereby the first binding region and second binding region are at opposite ends of the construct. Also provided is a method for detecting protein having certain amino acid sequences, the method comprising supplying a collection of proteins each with unknown amino acid sequences, contacting the collection with a moiety having a plurality of binding sites capable of binding with the protein having certain amino acid sequences so as to form a moiety-protein complex, and mixing the complex with a marker specific for the moiety in an amount sufficient to indicate existence of the complex.Type: GrantFiled: August 27, 2008Date of Patent: February 9, 2010Assignee: Uchicago Argonne, LLCInventors: Fred J. Stevens, Marianne Schiffer, Priscilla Wilkins-Stevens, W. Carey Hanly, Sandra L. Tollaksen
-
Patent number: 7655479Abstract: Luminescent semiconductor quantum dots (QDs) conjugated with biomolecules to serve as sensitive probes for early detection of the cancer cells, specifically for ovarian cancer and lung cancer, which represents the most lethal malignancies. The luminescence characterization of the bin-conjugated QDs with cancer specific antigens using linkage molecules. Photo-enhancement is measured at various laser density power, temperatures and laser wavelengths.Type: GrantFiled: June 30, 2005Date of Patent: February 2, 2010Assignees: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc., The Regents of the University of CaliforniaInventors: Tatyana A. Zhukov, Sergei Ostapenko, Rebecca Sutphen, Johnathan Lancaster, Thomas A. Sellers, Jin Z. Zhang
-
Patent number: 7642341Abstract: The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular MAb H33, to soluble JAM-C and JAM-B and to small molecules.Type: GrantFiled: December 18, 2003Date of Patent: January 5, 2010Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 7598051Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.Type: GrantFiled: October 14, 2005Date of Patent: October 6, 2009Assignee: Corixa CorporationInventors: Gary R Fanger, Steven P Fling
-
Patent number: 7579142Abstract: The present invention relates to a method for the selective purification of bacterial cells and/or cell components, whereby the purification is performed by means of a solid support.Type: GrantFiled: June 24, 2002Date of Patent: August 25, 2009Assignee: Profos AGInventors: Michael Schütz, Renate Grassl, Roman Meyer, Sibylle Frick, Ingrid Robl, Thomas Zander, Stefan Miller
-
Patent number: 7575873Abstract: The invention provides a novel human Mab Fab, cloned by phage display, and its use in diagnostic and therapeutic methods. In particular the invention provides a method for analyzing the OxLDL components of atherosclerotic plaques in vivo and a means to determine their relative pathology. As the method is based on a human Fab rather than a mouse Mab, the progress or regression of the disease may be monitored over time. The antibody may also be used for the analysis of surgical or serum samples ex vivo for the presence of OxLDL. The antibody may also be used to target therapeutic agents to the site of atherosclerotic plaques or may have use as a therapeutic agent itself.Type: GrantFiled: November 12, 2003Date of Patent: August 18, 2009Assignee: The Regents of the University of CaliforniaInventors: Joseph L. Witztum, Sotirios Tsimikas, Wulf Palinski
-
Patent number: 7575939Abstract: Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters.Type: GrantFiled: May 5, 2005Date of Patent: August 18, 2009Assignee: SRU Biosystems, Inc.Inventors: Brian T. Cunningham, Jane Pepper, Bo Lin, Peter Li, Homer Pien, Jean Qiu
-
Patent number: 7569390Abstract: A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.Type: GrantFiled: March 10, 2000Date of Patent: August 4, 2009Assignees: Medical Research Council, Scuola Internazionale Superiore Di Studi AvanzatiInventors: Tse Wai-Choi Eric, Terenos Rabbits, Antonio Cattaneo, Michela Visintin
-
Publication number: 20090186423Abstract: The present invention provides a characterization platform that can be used to assess the amount of different antibodies produced by a polyclonal cell line during production, as well as batch-to-batch consistency of the antibodies present in the polyclonal products. The structural characterization platform is based on removal of the heavy chains and separation of the light chains remaining via a chromatographic separation technique followed by mass spectrometry analysis on the intact light chain species.Type: ApplicationFiled: November 20, 2008Publication date: July 23, 2009Applicant: Symphogen A/SInventors: Torben P. FRANDSEN, Lone Kjaer RASMUSSEN, Anders ENGSTROM, Erland HOLMBERG, Pia PERSSON